1. Proceedings
  2. I3M
  3. 2019
  4. IWISH
  5. 10.46354/i3m.2019.iwish.016

Continuous glucose monitoring in acute stroke

  • a Laura Aponte-Becerra  , 
  • a Rodrigo Quispe  , 
  • a Laura Mendez-Pino  , 
  • a,b Vera Novak  , 
  • b Magdy Selim  , 
  • b Vasileios-Arsenios Lioutas   
  • aSAFE Laboratory, Department of Neurology, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, USA
  • bStroke Division, Department of Neurology, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, USA
Cite as
Aponte-Becerra L., Quispe R. C., Mendez-Pino L., Novak V., Selim M., Lioutas V.-A. (2019). Continuous glucose monitoring in acute stroke. Proceedings of the 8th International Workshop on Innovative Simulation for Healthcare (IWISH 2019), pp. 90-95. DOI: https://doi.org/10.46354/i3m.2019.iwish.016

Abstract

Hyperglycaemia upon admission is a pathophysiological response to acute brain ischemia that has been independently associated with high mortality rate and poor prognosis. Glycaemic variability (GV) has also shown association with poor clinical outcomes among stroke patients. GV is best assessed by continuous glucose monitoring (CGM), which enables consecutives glucose measurements every 5 minutes. This pilot study aimed: 1) To describe safety, feasibility and tolerability of CGM in the acute stroke setting; and 2) To compare CGM and conventional FS glucose-based monitoring regimen in terms of their relationship with GUA and the accuracy of hypoglycaemic episodes detection. Safety, feasibility and tolerability of CGM was excellent in our cohort of 23 patients with acute stroke (61% ischemic and 39% intracerebral haemorrhage) and there were no adverse events. CGM recorded ten hypoglycaemic episodes that were not detected by conventional FS monitoring. GUA was associated with coefficient of variation (CV) of CGM (p=0.03), CV of FS (p=0.01), standard deviation (SD) of CGM (p-value=0.01) and mean amplitude of glucose excursions (MAGE) (pvalue= 0.001).

References

  1. American Diabetes Association. 2019. “6. Glycaemic Targets: Standards of Medical Care in Diabetes— 2019.” Diabetes Care 42 (Supplement 1): S61–70.
  2. Capes, S. E., D. Hunt, K. Malmberg, P. Pathak, and H. C. Gerstein. 2001. “Stress Hyperglycaemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients: A Systematic Overview.” Stroke 32 (10): 2426–32.
  3. Danne, Thomas, Revital Nimri, Tadej Battelino, Richard M. Bergenstal, Kelly L. Close, J. Hans DeVries, Satish Garg, et al. 2017. “International Consensus on Use of Continuous Glucose Monitoring.” Diabetes Care 40 (12): 1631–40.
  4. Egi, Moritoki, Rinaldo Bellomo, and Michael C. Reade. 2009. “Is Reducing Variability of Blood Glucose the Real but Hidden Target of Intensive Insulin Therapy?” Critical Care (London, England) 13 (2): 302.
  5. Eslami, Saeid, Zhila Taherzadeh, Marcus J. Schultz, and Ameen Abu-Hanna. 2011. “Glucose Variability Measures and Their Effect on Mortality: A Systematic Review.” Intensive Care Medicine 37 (4): 583–93.
  6. Falciglia, Mercedes, Ron W. Freyberg, Peter L. Almenoff, David A. D’Alessio, and Marta L.
    Render. 2009. “Hyperglycaemia-Related Mortality in Critically Ill Patients Varies with Admission
    Diagnosis.” Critical Care Medicine 37 (12): 3001– 9.
  7. Fuentes, Blanca, José Castillo, Belén San José, Rogelio Leira, Joaquín Serena, José Vivancos, Antonio Dávalos, et al. 2009. “The Prognostic Value of Capillary Glucose Levels in Acute Stroke: The GLycemia in Acute Stroke (GLIAS) Study.” Stroke 40 (2): 562–68.
  8. Nathan R Hill. 2010. Glycaemic Variability Calculator: EasyGV. Oxford University Innovation. Retrieved from: https://innovation.ox.ac.uk/licencedetails/ glycaemic-variability-calculator-easygv/.
  9. Godoy, Daniel A., Mario Di Napoli, and Alejandro A. Rabinstein. 2010. “Treating Hyperglycaemia in Neurocritical Patients: Benefits and Perils.” Neurocritical Care 13 (3): 425–38.
  10. Graham, Brian B., Angela Keniston, Ognjen Gajic, Cesar A. Trillo Alvarez, Sofia Medvedev, and Ivor S.ouglas. 2010. “Diabetes Mellitus Does Not Adversely Affect Outcomes from a Critical
    Illness*.” Critical Care Medicine 38 (1): 16.
  11. Gray, Christopher S., Anthony J. Hildreth, Peter A Sandercock, Janice E. O’Connell, Donna E.
    Johnston, Niall E. F. Cartlidge, John M. Bamford, Oliver F. James, K. George M. M. Alberti, and
    GIST Trialists Collaboration. 2007. “Glucose- Potassium-Insulin Infusions in the Management of
    Post-Stroke Hyperglycaemia: The UK Glucose Insulin in Stroke Trial (GIST-UK).” The Lancet.
    Neurology 6 (5): 397–406
  12. Johnston, Karen C., Askiel Bruno, Qi Pauls, Christiana E. Hall, Kevin M. Barrett, William Barsan, Amy Fansler, et al. 2019. “Intensive vs Standard Treatment of Hyperglycaemia and Functional
    Outcome in Patients with Acute Ischemic Stroke: The SHINE Randomized Clinical Trial.” JAMA
    322 (4): 326–35.
  13. Kreisel, Stefan H., Undine M. Berschin, Hans-Peter Hammes, Hans Leweling, Thomas Bertsch,
    Michael G. Hennerici, and Stefan Schwarz. 2009. “Pragmatic Management of Hyperglycaemia in
    Acute Ischaemic Stroke: Safety and Feasibility of Intensive Intravenous Insulin Treatment.”
    Cerebrovascular Diseases (Basel, Switzerland) 27 (2): 167–75.
  14. Kruyt, Nyika D., Geert Jan Biessels, J. Hans Devries, and Yvo B. Roos. 2010. “Hyperglycaemia in Acute Ischemic Stroke: Pathophysiology and Clinical Management.” Nature Reviews. Neurology 6 (3): 145–55.
  15. Lanspa, Michael J., Justin Dickerson, Alan H. Morris, James F. Orme, John Holmen, and Eliotte L.
    Hirshberg. 2014. “Coefficient of Glucose Variation Is Independently Associated with Mortality in
    Critically Ill Patients Receiving Intravenous Insulin.” Critical Care (London, England) 18 (2): R86.
  16. Monnier, Louis, Claude Colette, and David R. Owens. 2008. “Glycaemic Variability: The Third
    Component of the Dysglycemia in Diabetes. Is It Important? How to Measure It?” Journal of
    Diabetes Science and Technology 2 (6): 1094– 1100.
  17. Monnier, Louis, Claude Colette, Anne Wojtusciszyn,Sylvie Dejager, Eric Renard, Nicolas Molinari, and David R. Owens. 2017. “Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.” Diabetes Care 40 (7): 832–38.
  18. Paciaroni, Maurizio, Giancarlo Agnelli, Valeria Caso, Francesco Corea, Walter Ageno, Andrea Alberti, Alessia Lanari, et al. 2009. “Acute Hyperglycaemia and Early Hemorrhagic Transformation in Ischemic Stroke.” Cerebrovascular Diseases (Basel, Switzerland) 28 (2): 119–23.
  19. Poppe, Alexandre Y., Sumit R. Majumdar, Thomas Jeerakathil, William Ghali, Alastair M. Buchan,
    Michael D. Hill, and Canadian Alteplase for Stroke Effectiveness Study Investigators. 2009.
    “Admission Hyperglycaemia Predicts a Worse Outcome in Stroke Patients Treated with
    Intravenous Thrombolysis.” Diabetes Care 32 (4): 617–22.
  20. Rabinstein, Alejandro A. 2009. “Hyperglycaemia in Critical Illness: Lessons from NICE-SUGAR.”
    Neurocritical Care 11 (1): 131–32
  21. Seners, Pierre, Guillaume Turc, Catherine Oppenheim, and Jean-Claude Baron. 2015. “Incidence, Causes and Predictors of Neurological Deterioration Occurring within 24 h Following Acute Ischaemic Stroke: A Systematic Review with Pathophysiological Implications.” Journal of Neurology, Neurosurgery, and Psychiatry 86 (1): 87–94
  22. Siegelaar, Sarah E, Maartje Hickmann, Joost BL Hoekstra, Frits Holleman, and J Hans DeVries.
    2011. “The Effect of Diabetes on Mortality in Critically Ill Patients: A Systematic Review and
    Meta-Analysis.” Critical Care 15 (5): R205
  23. Signal, Matthew, Christopher G. Pretty, J. Geoffrey Chase, Aaron Le Compte, and Geoffrey M. Shaw. 2010. “Continuous Glucose Monitors and the Burden of Tight Glycaemic Control in Critical Care: Can They Cure the Time Cost?” Journal of Diabetes Science and Technology 4 (3): 625–35. https://doi.org/10.1177/193229681000400317
  24. Staszewski, Jacek, Bogdan Brodacki, Jerzy Kotowicz, and Adam Stepien. 2011. “Intravenous Insulin Therapy in the Maintenance of Strict Glycaemic Control in Nondiabetic Acute Stroke Patients with Mild Hyperglycaemia.” Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association 20 (2): 150–54.
  25. Vaddiraju, Santhisagar, Diane J Burgess, Ioannis Tomazos, Faquir C Jain, and Fotios
    padimitrakopoulos. 2010. “Technologies for Continuous Glucose Monitoring: Current Problems
    and Future Promises.” Journal of Diabetes Science and Technology 4 (6): 1540–62.
  26. Wada Shinichi, Yoshimura Sohei, Inoue Manabu, Matsuki Takayuki, Arihiro Shoji, Koga Masatoshi, Kitazono Takanari, et al. 2018. “Outcome Prediction in Acute Stroke Patients by Continuous Glucose Monitoring.” Journal of the American Heart Association 7 (8): e008744.
  27. Weber, Christian, and Oliver Schnell. 2009. “The Assessment of Glycaemic Variability and Its
    Impact on Diabetes-Related Complications: An Overview.” Diabetes Technology & Therapeutics
    11 (10): 623–33.
  28. Yoo, Deok-Sang, Jane Chang, Joon-Tae Kim, Min-Ji Choi, Jina Choi, Kang-Ho Choi, Man-Seok Park, and Ki-Hyun Cho. 2014. “Various Blood Glucose Parameters That Indicate Hyperglycaemia after Intravenous Thrombolysis in Acute Ischemic
  29. Zijlstra, E., T. Heise, L. Nosek, L. Heinemann, and S. Heckermann. 2013. “Continuous Glucose
    Monitoring: Quality of Hypoglycaemia Detection.” Diabetes, Obesity & Metabolism 15 (2): 130–35.